AI4ChemoBrain is realised by a 5-partner consortium, all laboratories of the High Technology Network, to which two companies are added.
The members of the research laboratories involved have already collaborated in previous projects, offering guarantees for the feasibility and effective management of the project activities. In particular, the members of the grouping have already developed ML/AI models applied to the predictive medicine of cognitive decline and frailty (CIRI ICT and CIRI SDV, OPLON project, Smart Cities, MIUR), and worked on the integration of behavioural phenotype data with biomarkers with a view to predicting cognitive decline in various animal models (IRET, LTTA, CIRI SDV).
BIOPHARMANET-TEC has experience in evaluating the systemic impact of chemotherapeutics on the ageing trajectory in the laboratory animal. The grouping (CIRI SDV and IRET) has also experience in translating predictive models integrating functional phenotype and omics data from the preclinical to the clinical field, as already proposed in traumatic spinal cord injury (POR FESR project – Mat2Rep and Finalised Health project).
IRET Foundation is a scientific research organisation in the biomedical field and an accredited laboratory of the High Technology Network. It hosts the Tecnopolo di Bologna – Ozzano site, of which it is the managing body.
CIRI ICT – University of Bologna is an industrial research laboratory of the University of Bologna, accredited as a High Technology Network laboratory. CIRI ICT aims to promote, coordinate and carry out activities of industrial research, promotion of research results and technology transfer in the field of information and communication technologies, to meet the needs of the industrial world and sustainability. In particular, the Center promotes solutions to address societal challenges given by the environment, health, and aging; to support the organization of enterprises through automation and intelligent management of information, processes, and products; and to respond to people’s needs.
LTTA – University of Ferrara is an Industrial research and technology transfer laboratory accredited as a High Technology Network laboratory that is based on the coordinated activity of services with complementary competencies strongly directed to innovation and technology transfer in the field of Life Sciences and Health Technologies. LTTA offers, among other activities, “Preclinical testing” services through in vitro and in vivo assays in animal models of pathology, including Alzheimer’s disease. It has established experience in collaborations with pharmaceutical companies in preclinical research, and has developed numerous studies in animal models of cognitive decline. These activities and established pharmacological knowledge represent necessary and functional skills for the proposed project.
Biopharmanet-TEC – University of Parma is an industrial research laboratory of the University of Parma, accredited as a High Technology Network laboratory. The Biopharmanet-TEC Center brings together researchers belonging to five departments of technical scientific and biomedical areas to promote, manage and participate in projects in the areas of industrial research and technology transfer on topics covering: pharmaceutical technology and chemistry; drug development; experimental pharmacology and toxicology; pharmaceutical engineering and process technology; and biochemistry and molecular biology and recombinant DNA technologies.
Alfasigma is one of Italy’s leading pharmaceutical companies with a strong international focus. It is a Group operating in more than 100 countries worldwide in which about 4,000 people work in research, development, production and distribution. With more than 70 years of history, Alfasigma has a long experience in the development of innovative therapeutic indications and in Italy it is a leader in the market of prescription products where, in addition to its strong focus on gastro-intestinal, it is present in several primary care therapeutic areas. It is recognized by the consumer public for some well-known self-medication references and dietary supplements rooted in the experience of families.
Wellmicro® is the first Italian Microbiome Based company offering metagenomic sequencing services exclusively dedicated to analysis and research in the field of human, animal and environmental microbiome. Wellmicro® develops innovative analysis methodologies also based on proprietary bioinformatics tools that exploit artificial intelligence models such as, for example, machine learning. Following patented and scientifically validated methods, it has developed a functional interpretation method for metagenomic analysis of the gut and vaginal microbiome by evaluating its possible impact on the individual’s state of well-being/health.
